Clinical Trial Update: A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures [Phase 2]

View source ↗

Summary

Phase 2 study assessing the effectiveness and safety of NBI-921352 when used with anti-seizure medications in adults with focal onset seizures has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Onset Epilepsy
• Focal Onset Seizures

Drugs mentioned

• NBI-921352 (NBI-921352)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Focal Onset Seizure, Focal Onset Epilepsy | Phase 2 | Status: COMPLETED